This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
2
0
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Needham analyst Ami Fadia downgraded the rating for Biogen Inc. (NASDAQ:BIIB) from Buy to Hold and maintained the price target of $270. Biogen shares closed at $159.99 on Friday. See how other analysts view this stock.
- Wolfe Research analyst Jacob Lacks downgraded the rating for Matson, Inc. (NYSE:MATX) from Outperform to Peer Perform. Matson shares closed at $160.65 on Friday. See …
Full story available on Benzinga.com
Visited 2 times, 1 visit(s) today